Asosiy kontentga oʻtish
Maqola

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Ahmed ElfadadnyLaboratory of Internal Medicine, Cooperative Division of Veterinary Sciences, Tokyo University of Agriculture and Technology, Fuchu, JapanRokaia F. RagabLaboratory of Internal Medicine, Cooperative Division of Veterinary Sciences, Tokyo University of Agriculture and Technology, Fuchu, JapanMaha AlharbiDepartment of Biology, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi ArabiaFarhad BadshahState Key Laboratory of Animal Biotech Breeding, Institute of Animal Science, Chinese Academy of Agricultural Science, Beijing, ChinaEliana Ibáñez-ArancibiaLaboratory of Engineering, Biotechnology and Applied Biochemistry - LIBBA, Department of Chemical Engineering, Faculty of Engineering and Science, La Frontera University, Temuco, ChileAhmed FaragDepartment of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, EgyptAmin Omar HendawyDepartment of Animal and Poultry Production, Faculty of Agriculture, Damanhour University, Damanhour, EgyptPatricio De los Ríos-EscalanteDepartment of Biological and Chemical Sciences, Faculty of Natural Resources, Catholic University of Temuco, Temuco, ChileMohamed AboubakrDepartment of Pharmacology, Faculty of Veterinary Medicine, Benha University, Moshtohor, Toukh, Qaliobiya, EgyptShadi A. ZakaiDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaWedad M. NageebDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2024en
ABI

Annotatsiya

Pseudomonas aeruginosa , a Gram-negative bacterium, is recognized for its adaptability and opportunistic nature. It poses a substantial challenge in clinical settings due to its complicated antibiotic resistance mechanisms, biofilm formation, and capacity for persistent infections in both animal and human hosts. Recent studies revealed a potential zoonotic transmission of P. aeruginosa between animals, the environment, and human populations which highlights awareness of this microbe. Implementation of the One Health approach, which underscores the connection between human, animal, and environmental health, we aim to offer a comprehensive perspective on the current landscape of P. aeruginosa management. This review presents innovative strategies designed to counteract P. aeruginosa infections. Traditional antibiotics, while effective in many cases, are increasingly compromised by the development of multidrug-resistant strains. Non-antibiotic avenues, such as quorum sensing inhibition, phage therapy, and nanoparticle-based treatments, are emerging as promising alternatives. However, their clinical application encounters obstacles like cost, side effects, and safety concerns. Effectively addressing P. aeruginosa infections necessitates persistent research efforts, advancements in clinical development, and a comprehension of host-pathogen interactions to deal with this resilient pathogen.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba